217:(which codes for the KIT protein that regulates cell growth and specifically), specifically around codon 816 with the common one being asp816val, have been suspected to be associated with MCAS and is also associated to most systemic mastocytosis patients. It has been found that MCAS patients tend to have a wider range of KIT mutations around all domains of the protein and multiple at the same time rather than a single one, which could be a potential cause of the heterogeneity of the presenting symptoms of MCAS. Symptoms of MCAS are caused by excessive chemical mediators released by mast cells. Mediators include
245:, allergic rhinitis, and wheezing. Systemic mast cell activation presents with symptoms involving two or more organ systems (skin: urticaria, angioedema, and flushing; gastrointestinal: nausea, vomiting, diarrhea, and abdominal cramping; cardiovascular: hypotensive syncope or near syncope and tachycardia; respiratory: wheezing; naso-ocular: conjunctival injection, pruritus, and nasal stuffiness). This can result from the release of mediators from a specific site, such as the skin or mucosal tissue, or activation of mast cells around the vasculature.
265:(AAAI), the most precise method of diagnosing MCAS is through a bone marrow biopsy and aspirate. This method is commonly used to diagnose systemic mastocytosis, and the presence of SM increases the possibility of subsequently having MCAS. In addition, other common laboratory tests including KIT-D816X mutational analysis and flow cytometry analysis seeking co-expression of CD117 and CD25 are also commended for diagnosing clonal MCAS.
1499:
A diverse range of mast cell stabilizing compounds have been identified in the last decade from; natural, biological and synthetic sources to drugs already in clinical uses for other indications. Although in many cases, the precise mode of action of these molecules is unclear, all of these substances
89:
Because degranulation events can be triggered in various locations within the body, MCAS can present with a wide range of symptoms in multiple body systems. These symptoms may range from digestive discomfort to chronic pain, mental issues, or full-scale anaphylactic reactions. Symptoms typically wax
253:
MCAS is often difficult to identify due to the heterogeneity of symptoms and the "lack of flagrant acute presentation". Many of the numerous symptoms are non-specific in nature. Diagnostic criteria were proposed in 2010 and revised in 2019. Mast cell activation was assigned an
676:
Conway AE, Verdi M, Shaker MS, Bernstein JA, Beamish CC, Morse R, Madan J, Lee MW, Sussman G, Al-Nimr A, Hand M, Albert DA (March 2024). "Beyond
Confirmed Mast Cell Activation Syndrome: Approaching Patients With Dysautonomia and Related Conditions".
1153:"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology"
1522:
Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, Valent P (2007). "Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome".
1644:
1629:
1150:
Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, Matito A, Broesby-Olsen S, Siebenhaar F, Lange M, Niedoszytko M, Castells M, Oude
Elberink JN, Bonadonna P, Zanotti R (January 2016).
712:
GĂĽlen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, Niedoszytko M, Nedoszytko B, Oude
Elberink HN, Butterfield JH, Sperr WR, Alvarez-Twose I, Horny HP, Sotlar K, Schwaab J (November 2021).
80:
MCAS is an umbrella term that describes a set of symptoms; it is not a specific diagnosis. Multiple diagnostic schemes for MCAS have been proposed. MCAS has been increasingly over-diagnosed or misdiagnosed.
1500:
have demonstrated mast cell stabilization activity and therefore may have potential therapeutic use in the treatment of allergic and related diseases where mast cells are intrinsically involved.
457:
Valent P, Hartmann K, Bonadonna P, GĂĽlen T, Brockow K, Alvarez-Twose I, Hermine O, Niedoszytko M, Carter MC, Hoermann G, Butterfield JH, Lyons JJ, Sperr WR, Greiner G, Sotlar K (2022-05-24).
1312:
Afrin LB, Ackerley MB, Bluestein LS, Brewer JH, Brook JB, Buchanan AD, Cuni JR, Davey WP, Dempsey TT, Dorff SR, Dubravec MS, Guggenheim AG, Hindman KJ, Hoffman B, Kaufman DL (2021-05-01).
274:
Recurrent abdominal pain, diarrhea, flushing, itching, nasal congestion, coughing, chest tightness, wheezing, lightheadedness (usually a combination of some of these symptoms is present)
241:
Mast cell activation can be localized or systemic, but a diagnosis of MCAS requires systemic symptoms. Some examples of tissue specific consequences of mast cell activation include
277:
Laboratory evidence of mast cell mediator (elevated serum tryptase, N-methyl histamine, prostaglandin D2 or 11-beta- prostaglandin F2 alpha, leukotriene E4 and others)
262:
931:
1046:"Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects"
77:
or near-anaphylaxis attacks. Primary symptoms include cardiovascular, dermatological, gastrointestinal, neurological, and respiratory problems.
1506:
1424:
Castells M, Butterfield J (April 2019). "Mast Cell
Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management".
1022:
268:
Although different diagnostic criteria are published, a commonly used strategy to diagnose patients is to use all three of the following:
986:"Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder"
380:, can be very helpful in reducing inflammation in some patients, while other patients can have dangerous reactions to these drugs
1568:"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis"
967:
213:
There are many causes of mast cell activation, including allergy. Genetics may play a role. In particular, Mutations of the
73:
inappropriately and excessively release chemical mediators, resulting in a range of chronic symptoms, sometimes including
373:
1129:
768:
512:
1209:"AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management"
791:"Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review"
715:"Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review"
459:"Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium"
1683:
1291:
415:
in 1991, and named in 2007, following a build-up of evidence featured in papers by
Sonneck et al. and Akin et al.
958:
Afrin L (2013). "Prevention, diagnosis, and management of mast cell activation syndrome.". In Murray D (ed.).
62:
937:
846:
Weiler CR (February 2020). "Mast Cell
Activation Syndrome: Tools for Diagnosis and Differential Diagnosis".
790:
90:
and wane over time, varying in severity and duration. Many signs and symptoms are the same as those for
285:
280:
Improvement in symptoms with the use of medications that block or treat elevations in these mediators
1208:
1656:
1503:
1566:
Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD (October 2007).
985:
338:
317:
930:
Afrin L (2013). "Presentation, Diagnosis, and
Management of Mast Cell Activation Syndrome.".
429:
412:
300:
8:
1648:
1638:
383:
983:
Molderings GJ, Kolck UW, Scheurlen C, BrĂĽss M, Homann J, Von KĂĽgelgen I (January 2007).
1688:
1592:
1567:
1548:
1485:
1460:
1395:
871:
828:
760:
613:
588:
564:
504:
367:
137:
896:"A concise, practical guide to diagnostic assessment for mast cell activation disease"
1597:
1540:
1490:
1441:
1387:
1343:
1335:
1265:
1230:
1182:
1174:
1121:
1113:
1074:
1066:
1014:
1006:
963:
875:
863:
832:
820:
764:
752:
744:
694:
653:
618:
556:
508:
496:
488:
36:
1661:
1552:
568:
1587:
1579:
1532:
1480:
1472:
1433:
1399:
1379:
1325:
1257:
1220:
1164:
1105:
1058:
998:
907:
855:
810:
802:
734:
726:
686:
645:
608:
600:
546:
478:
470:
434:
69:); the other type is idiopathic MCAD. MCAS is an immunological condition in which
1583:
1510:
351:
308:
304:
122:
1437:
1261:
1225:
1169:
1152:
1109:
859:
806:
730:
690:
636:
Akin C (May 2015). "Mast cell activation syndromes presenting as anaphylaxis".
604:
474:
392:
94:, because both conditions result in too many mediators released by mast cells.
1383:
1062:
1002:
649:
258:
code (D89.40, along with subtype codes D89.41-43 and D89.49) in
October 2016.
1677:
1339:
1178:
1117:
1070:
1010:
748:
492:
226:
1045:
1601:
1544:
1494:
1445:
1391:
1347:
1269:
1234:
1186:
1125:
1093:
1078:
1018:
867:
824:
756:
714:
698:
657:
622:
560:
500:
458:
411:
The condition was hypothesized by the pharmacologists Oates and
Roberts of
329:
218:
91:
19:
1621:
960:
Mast cells: Phenotypic features, biological functions and role in immunity
933:
Mast Cells: Phenotypic
Features, Biological Functions and Role in Immunity
1330:
1313:
355:
200:
145:
74:
1283:
815:
739:
483:
387:
346:
342:
333:
321:
222:
214:
141:
133:
41:
1536:
1476:
912:
895:
551:
534:
1633:
325:
312:
70:
1314:"Diagnosis of mast cell activation syndrome: a global "consensus-2""
1043:
Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T (2010-12-01).
363:
359:
230:
424:
377:
45:
1149:
535:"Mast cell activation syndromes: definition and classification"
255:
1565:
272:
Symptoms consistent with chronic/recurrent mast cell release:
1521:
982:
589:"Mast cell activation syndrome: Proposed diagnostic criteria"
242:
155:
diarrhea and/or constipation, cramping, intestinal discomfort
1311:
711:
456:
1426:
The Journal of Allergy and Clinical Immunology: In Practice
789:
GĂĽlen T, Akin C, Bonadonna P, et al. (November 2021).
719:
The Journal of Allergy and Clinical Immunology. In Practice
463:
The Journal of Allergy and Clinical Immunology. In Practice
1207:
Weiler CR, Austen KF, Akin C, et al. (October 2019).
675:
1042:
1248:
Akin C (August 2017). "Mast cell activation syndromes".
1452:
1370:
Frieri M (June 2018). "Mast Cell Activation Syndrome".
1202:
1200:
1198:
1196:
1611:
1193:
1423:
263:
American Academy of Allergy, Asthma, and Immunology
132:lightheadedness, dizziness, non-cardiac chestpain,
1504:Table 1: Naturally occurring mast cell stabilizers
1044:
984:
788:
586:
452:
450:
1675:
1525:International Archives of Allergy and Immunology
1206:
936:. Nova Science. pp. 155–232. Archived from
1419:
1417:
1415:
1413:
1411:
1409:
925:
923:
893:
638:Immunology and Allergy Clinics of North America
587:Akin C, Valent P, Metcalfe DD (December 2010).
447:
1250:The Journal of Allergy and Clinical Immunology
1213:The Journal of Allergy and Clinical Immunology
1157:The Journal of Allergy and Clinical Immunology
1098:The Journal of Allergy and Clinical Immunology
962:. Nova Sciences Publishers. pp. 155–231.
671:
669:
667:
593:The Journal of Allergy and Clinical Immunology
61:) is a term referring to one of two types of
1461:"Twenty-first century mast cell stabilizers"
1406:
1372:Clinical Reviews in Allergy & Immunology
920:
664:
1591:
1484:
1458:
1365:
1363:
1361:
1359:
1357:
1329:
1224:
1168:
911:
894:Afrin LB, Molderings GJ (February 2014).
814:
738:
612:
550:
482:
1288:TMS - The Mast Cell Disease Society, Inc
991:Scandinavian Journal of Gastroenterology
782:
889:
887:
885:
288:has not published diagnostic criteria.
161:swallowing difficulty, throat tightness
1676:
1369:
1354:
845:
532:
957:
929:
582:
580:
578:
526:
113:either a reddish or a pale complexion
84:
1459:Finn DF, Walsh JJ (September 2013).
1247:
1091:
882:
635:
629:
403:The prognosis of MCAS is uncertain.
374:Nonsteroidal anti-inflammatory drugs
296:Pharmacological treatments include:
362:as well as natural products (e.g.,
13:
575:
236:
14:
1700:
1284:"Mast Cell Disease ICD-10 Codes"
1094:"Mast cell activation syndromes"
1559:
1515:
1465:British Journal of Pharmacology
1305:
1294:from the original on 2024-03-21
1276:
1241:
1143:
1132:from the original on 2023-01-30
1085:
1036:
1025:from the original on 2023-03-27
976:
951:
771:from the original on 2023-02-10
515:from the original on 2023-02-11
839:
705:
192:congestion, coughing, wheezing
1:
440:
158:nausea, vomiting, acid reflux
63:mast cell activation disorder
55:Mast cell activation syndrome
31:Mast cell activation syndrome
1584:10.1182/blood-2006-06-028100
848:J Allergy Clin Immunol Pract
795:J Allergy Clin Immunol Pract
679:J Allergy Clin Immunol Pract
398:
291:
248:
7:
900:World Journal of Hematology
418:
10:
1705:
1438:10.1016/j.jaip.2019.02.002
1262:10.1016/j.jaci.2017.06.007
1226:10.1016/j.jaci.2019.08.023
1170:10.1016/j.jaci.2015.08.034
1110:10.1016/j.jaci.2017.06.007
860:10.1016/j.jaip.2019.08.022
807:10.1016/j.jaip.2021.06.011
731:10.1016/j.jaip.2021.06.011
691:10.1016/j.jaip.2024.03.019
605:10.1016/j.jaci.2010.08.035
475:10.1016/j.jaip.2022.05.007
406:
17:
1615:
1384:10.1007/s12016-015-8487-6
1063:10.1007/s00251-010-0474-8
1003:10.1080/00365520701245744
650:10.1016/j.iac.2015.01.010
286:World Health Organization
208:
97:Common symptoms include:
35:
30:
18:Not to be confused with
1684:Immune system disorders
533:Valent P (April 2013).
181:mild cognitive problems
1092:Akin C (August 2017).
430:Histamine intolerance
413:Vanderbilt University
384:Monoclonal antibodies
301:Mast cell stabilizers
178:lack of concentration
1331:10.1515/dx-2020-0005
311:stabilizers such as
1509:2020-11-02 at the
599:(6): 1099–104.e4.
184:sleep disturbances
85:Signs and symptoms
1671:
1670:
1537:10.1159/000096442
1477:10.1111/bph.12138
969:978-1-62618-166-3
913:10.5315/wjh.v3.i1
801:(11): 3918–3928.
725:(11): 3918–3928.
552:10.1111/all.12126
339:H2-antihistamines
318:H1-antihistamines
261:According to the
166:Neuropsychiatric
152:Gastrointestinal
52:
51:
25:Medical condition
1696:
1613:
1612:
1606:
1605:
1595:
1563:
1557:
1556:
1519:
1513:
1502:
1488:
1456:
1450:
1449:
1432:(4): 1097–1106.
1421:
1404:
1403:
1367:
1352:
1351:
1333:
1309:
1303:
1302:
1300:
1299:
1280:
1274:
1273:
1245:
1239:
1238:
1228:
1204:
1191:
1190:
1172:
1147:
1141:
1140:
1138:
1137:
1089:
1083:
1082:
1048:
1040:
1034:
1033:
1031:
1030:
997:(9): 1045–1053.
988:
980:
974:
973:
955:
949:
948:
946:
945:
927:
918:
917:
915:
891:
880:
879:
843:
837:
836:
818:
786:
780:
779:
777:
776:
742:
709:
703:
702:
685:(7): 1738–1750.
673:
662:
661:
633:
627:
626:
616:
584:
573:
572:
554:
530:
524:
523:
521:
520:
486:
469:(8): 1941–1950.
454:
435:Immunoglobulin E
352:Antileukotrienes
175:fatigue/lethargy
28:
27:
1704:
1703:
1699:
1698:
1697:
1695:
1694:
1693:
1674:
1673:
1672:
1667:
1666:
1624:
1610:
1609:
1564:
1560:
1520:
1516:
1511:Wayback Machine
1457:
1453:
1422:
1407:
1368:
1355:
1310:
1306:
1297:
1295:
1282:
1281:
1277:
1246:
1242:
1205:
1194:
1148:
1144:
1135:
1133:
1090:
1086:
1057:(11): 721–727.
1041:
1037:
1028:
1026:
981:
977:
970:
956:
952:
943:
941:
928:
921:
892:
883:
844:
840:
787:
783:
774:
772:
710:
706:
674:
665:
634:
630:
585:
576:
531:
527:
518:
516:
455:
448:
443:
421:
409:
401:
393:Corticosteroids
368:St. John's wort
305:cromolyn sodium
294:
273:
251:
239:
237:Pathophysiology
211:
129:Cardiovascular
123:dermatographism
119:burning feeling
87:
26:
23:
12:
11:
5:
1702:
1692:
1691:
1686:
1669:
1668:
1665:
1664:
1653:
1641:
1625:
1620:
1619:
1617:
1616:Classification
1608:
1607:
1558:
1514:
1451:
1405:
1378:(3): 353–365.
1353:
1324:(2): 137–152.
1304:
1275:
1256:(2): 349–355.
1240:
1219:(4): 883–896.
1192:
1142:
1104:(2): 349–355.
1084:
1051:Immunogenetics
1035:
975:
968:
950:
919:
881:
854:(2): 498–506.
838:
781:
704:
663:
628:
574:
525:
445:
444:
442:
439:
438:
437:
432:
427:
420:
417:
408:
405:
400:
397:
396:
395:
390:
381:
371:
349:
336:
315:
293:
290:
282:
281:
278:
275:
250:
247:
238:
235:
210:
207:
206:
205:
204:
203:
195:
194:
193:
187:
186:
185:
182:
179:
176:
173:
170:
164:
163:
162:
159:
156:
150:
149:
148:
127:
126:
125:
120:
117:
114:
111:
108:
105:
86:
83:
50:
49:
39:
33:
32:
24:
9:
6:
4:
3:
2:
1701:
1690:
1687:
1685:
1682:
1681:
1679:
1663:
1659:
1658:
1654:
1651:
1650:
1646:
1642:
1640:
1636:
1635:
1631:
1627:
1626:
1623:
1618:
1614:
1603:
1599:
1594:
1589:
1585:
1581:
1578:(7): 2331–3.
1577:
1573:
1569:
1562:
1554:
1550:
1546:
1542:
1538:
1534:
1531:(2): 158–64.
1530:
1526:
1518:
1512:
1508:
1505:
1501:
1496:
1492:
1487:
1482:
1478:
1474:
1470:
1466:
1462:
1455:
1447:
1443:
1439:
1435:
1431:
1427:
1420:
1418:
1416:
1414:
1412:
1410:
1401:
1397:
1393:
1389:
1385:
1381:
1377:
1373:
1366:
1364:
1362:
1360:
1358:
1349:
1345:
1341:
1337:
1332:
1327:
1323:
1319:
1315:
1308:
1293:
1289:
1285:
1279:
1271:
1267:
1263:
1259:
1255:
1251:
1244:
1236:
1232:
1227:
1222:
1218:
1214:
1210:
1203:
1201:
1199:
1197:
1188:
1184:
1180:
1176:
1171:
1166:
1162:
1158:
1154:
1146:
1131:
1127:
1123:
1119:
1115:
1111:
1107:
1103:
1099:
1095:
1088:
1080:
1076:
1072:
1068:
1064:
1060:
1056:
1052:
1047:
1039:
1024:
1020:
1016:
1012:
1008:
1004:
1000:
996:
992:
987:
979:
971:
965:
961:
954:
940:on 2018-08-18
939:
935:
934:
926:
924:
914:
909:
905:
901:
897:
890:
888:
886:
877:
873:
869:
865:
861:
857:
853:
849:
842:
834:
830:
826:
822:
817:
812:
808:
804:
800:
796:
792:
785:
770:
766:
762:
758:
754:
750:
746:
741:
736:
732:
728:
724:
720:
716:
708:
700:
696:
692:
688:
684:
680:
672:
670:
668:
659:
655:
651:
647:
644:(2): 277–85.
643:
639:
632:
624:
620:
615:
610:
606:
602:
598:
594:
590:
583:
581:
579:
570:
566:
562:
558:
553:
548:
545:(4): 417–24.
544:
540:
536:
529:
514:
510:
506:
502:
498:
494:
490:
485:
480:
476:
472:
468:
464:
460:
453:
451:
446:
436:
433:
431:
428:
426:
423:
422:
416:
414:
404:
394:
391:
389:
385:
382:
379:
375:
372:
369:
365:
361:
357:
353:
350:
348:
344:
340:
337:
335:
331:
327:
323:
319:
316:
314:
310:
306:
302:
299:
298:
297:
289:
287:
279:
276:
271:
270:
269:
266:
264:
259:
257:
246:
244:
234:
232:
228:
227:prostaglandin
224:
220:
216:
202:
199:
198:
196:
191:
190:
188:
183:
180:
177:
174:
171:
168:
167:
165:
160:
157:
154:
153:
151:
147:
143:
139:
135:
131:
130:
128:
124:
121:
118:
115:
112:
110:easy bruising
109:
106:
103:
102:
101:Dermatologic
100:
99:
98:
95:
93:
82:
78:
76:
72:
68:
64:
60:
56:
47:
43:
40:
38:
34:
29:
21:
16:
1655:
1643:
1628:
1575:
1571:
1561:
1528:
1524:
1517:
1498:
1471:(1): 23–37.
1468:
1464:
1454:
1429:
1425:
1375:
1371:
1321:
1317:
1307:
1296:. Retrieved
1287:
1278:
1253:
1249:
1243:
1216:
1212:
1163:(1): 35–45.
1160:
1156:
1145:
1134:. Retrieved
1101:
1097:
1087:
1054:
1050:
1038:
1027:. Retrieved
994:
990:
978:
959:
953:
942:. Retrieved
938:the original
932:
903:
899:
851:
847:
841:
816:10261/268013
798:
794:
784:
773:. Retrieved
740:10261/268013
722:
718:
707:
682:
678:
641:
637:
631:
596:
592:
542:
538:
528:
517:. Retrieved
484:10261/296655
466:
462:
410:
402:
376:, including
330:fexofenadine
303:, including
295:
283:
267:
260:
252:
240:
219:leukotrienes
212:
189:Respiratory
96:
92:mastocytosis
88:
79:
66:
58:
54:
53:
20:Mastocytosis
15:
356:montelukast
201:anaphylaxis
146:tachycardia
75:anaphylaxis
1678:Categories
1662:D000090267
1298:2024-03-21
1136:2023-02-10
1029:2023-11-18
944:2015-10-13
906:(1): 1–7.
775:2023-02-10
519:2023-02-10
441:References
388:omalizumab
386:, such as
354:, such as
347:famotidine
343:ranitidine
341:, such as
334:loratadine
322:cetirizine
320:, such as
223:histamines
142:arrhythmia
134:presyncope
71:mast cells
42:Immunology
1689:Syndromes
1340:2194-802X
1318:Diagnosis
1179:1097-6825
1118:1097-6825
1071:1432-1211
1011:0036-5521
876:203814795
833:235634993
765:235634993
749:2213-2201
509:249073293
493:2213-2201
399:Prognosis
370:extracts)
326:ketotifen
313:quercetin
292:Treatment
249:Diagnosis
243:urticaria
197:Systemic
169:brain fog
116:itchiness
37:Specialty
1602:17638853
1553:25058981
1545:17057414
1507:Archived
1495:23441583
1446:30961835
1392:25944644
1348:32324159
1292:Archived
1270:28780942
1235:31476322
1187:26476479
1130:Archived
1126:28780942
1079:20838788
1023:Archived
1019:17710669
868:31470118
825:34166845
769:Archived
757:34166845
699:38499084
658:25841551
623:21035176
569:43636053
561:23409940
513:Archived
501:35623575
419:See also
364:curcumin
360:zileuton
231:tryptase
215:KIT gene
172:headache
104:flushing
1652:: 279.8
1593:1988935
1486:3764846
1400:5723622
614:3753019
539:Allergy
407:History
378:aspirin
309:natural
138:syncope
46:Allergy
1600:
1590:
1551:
1543:
1493:
1483:
1444:
1398:
1390:
1346:
1338:
1268:
1233:
1185:
1177:
1124:
1116:
1077:
1069:
1017:
1009:
966:
874:
866:
831:
823:
763:
755:
747:
697:
656:
621:
611:
567:
559:
507:
499:
491:
256:ICD-10
229:, and
209:Causes
1639:D89.4
1634:10-CM
1572:Blood
1549:S2CID
1396:S2CID
872:S2CID
829:S2CID
761:S2CID
565:S2CID
505:S2CID
425:FcεRI
107:hives
1657:MeSH
1649:9-CM
1598:PMID
1541:PMID
1491:PMID
1442:PMID
1388:PMID
1344:PMID
1336:ISSN
1266:PMID
1231:PMID
1183:PMID
1175:ISSN
1122:PMID
1114:ISSN
1075:PMID
1067:ISSN
1015:PMID
1007:ISSN
964:ISBN
864:PMID
821:PMID
753:PMID
745:ISSN
695:PMID
654:PMID
619:PMID
557:PMID
497:PMID
489:ISSN
307:and
284:The
67:MCAD
59:MCAS
1645:ICD
1630:ICD
1588:PMC
1580:doi
1576:110
1533:doi
1529:142
1481:PMC
1473:doi
1469:170
1434:doi
1380:doi
1326:doi
1258:doi
1254:140
1221:doi
1217:144
1165:doi
1161:137
1106:doi
1102:140
1059:doi
999:doi
908:doi
856:doi
811:hdl
803:doi
735:hdl
727:doi
687:doi
646:doi
609:PMC
601:doi
597:126
547:doi
479:hdl
471:doi
366:or
358:or
345:or
332:or
328:or
324:or
1680::
1660::
1637::
1596:.
1586:.
1574:.
1570:.
1547:.
1539:.
1527:.
1497:.
1489:.
1479:.
1467:.
1463:.
1440:.
1428:.
1408:^
1394:.
1386:.
1376:54
1374:.
1356:^
1342:.
1334:.
1320:.
1316:.
1290:.
1286:.
1264:.
1252:.
1229:.
1215:.
1211:.
1195:^
1181:.
1173:.
1159:.
1155:.
1128:.
1120:.
1112:.
1100:.
1096:.
1073:.
1065:.
1055:62
1053:.
1049:.
1021:.
1013:.
1005:.
995:42
993:.
989:.
922:^
902:.
898:.
884:^
870:.
862:.
850:.
827:.
819:.
809:.
797:.
793:.
767:.
759:.
751:.
743:.
733:.
721:.
717:.
693:.
683:12
681:.
666:^
652:.
642:35
640:.
617:.
607:.
595:.
591:.
577:^
563:.
555:.
543:68
541:.
537:.
511:.
503:.
495:.
487:.
477:.
467:10
465:.
461:.
449:^
233:.
225:,
221:,
144:,
140:,
136:,
1647:-
1632:-
1622:D
1604:.
1582::
1555:.
1535::
1475::
1448:.
1436::
1430:7
1402:.
1382::
1350:.
1328::
1322:8
1301:.
1272:.
1260::
1237:.
1223::
1189:.
1167::
1139:.
1108::
1081:.
1061::
1032:.
1001::
972:.
947:.
916:.
910::
904:3
878:.
858::
852:8
835:.
813::
805::
799:9
778:.
737::
729::
723:9
701:.
689::
660:.
648::
625:.
603::
571:.
549::
522:.
481::
473::
65:(
57:(
48:)
44:(
22:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.